According to a new report by Polaris Market Research, the global semaglutide market was valued at USD 32.22 billion in 2025 and is projected to reach USD 81.08 billion by 2034, expanding at a CAGR of 10.8% over the forecast period. Growth is underpinned by the rising global prevalence of type 2 diabetes and obesity, expanding oral and injectable formulation options, and continued clinical evidence supporting semaglutide's dual metabolic benefits.

What Is Driving Semaglutide Market Growth?

Demand is climbing as the global obesity and diabetes burden converges with expanding treatment access. Manufacturers are prioritizing product diversification — from once-weekly injectables to daily oral tablets — pushing semaglutide adoption across broader patient populations. Polaris analysts note that the World Obesity Atlas projects adult obesity rates to climb more than 115% by 2030, positioning the obesity-treatment application for sustained double-digit growth through 2034, with type 2 diabetes remaining the largest revenue contributor and obesity posting the fastest incremental gains.

Key Trends Shaping the Semaglutide Industry

Expansion of Oral and Next-Generation Formulations

Oral semaglutide — Rybelsus, and now Wegovy tablets — is broadening access among patients hesitant to use injectables. Novo Nordisk reported Wegovy tablets surpassed three million prescriptions within roughly five months of their January 2026 launch, with the majority going to patients new to GLP-1 therapy, evidence of the formulation shift's impact on treatment adherence.

Patent Expiry and Rising Generic Competition

Key products including Ozempic, Rybelsus, and Wegovy face patent expirations between 2026 and 2032. As exclusivity lapses in markets such as India, China, Brazil, Canada, and Turkey, generic and biosimilar entrants are expected to intensify competitive-landscape pressure while improving affordability and broadening patient access.

Regulatory Scrutiny of Compounded and Counterfeit Products

Rising demand has fueled unauthorized and counterfeit semaglutide circulation. The FDA has logged hundreds of adverse events tied to compounded and counterfeit versions and has tightened its compounding framework now that supply shortages are resolved, a regulatory shift that is reshaping prescribing behavior and market outlook.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/semaglutide-market 

Market Segmentation: Breaking Down the Semaglutide Market

Polaris segments the semaglutide market by product, application, route of administration, distribution channel, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Product

The Ozempic segment led the market in 2025, accounting for 51.9% of revenue, on the strength of its long clinical track record in type 2 diabetes management and high physician familiarity. Expanded-access moves, such as the February 2026 Abbott–Novo Nordisk India partnership to launch a secondary Ozempic brand, continue to reinforce this leadership position.

By Application

The type 2 diabetes mellitus segment held the largest share in 2025 at 66.7%, reflecting semaglutide's original approved indication and the extensive prescriber trust built over years of clinical use. The obesity segment is projected to expand at the fastest CAGR through 2034 as chronic-disease recognition and dedicated weight-management approvals unlock a substantially larger patient base.

By Route of Administration

Parenteral (injectable) formulations held the largest share at 78.4% in 2025, reflecting the established patient base for Ozempic and Wegovy. The oral segment is set to post the fastest growth as Rybelsus and Wegovy tablets remove the needle-aversion barrier that has historically limited treatment uptake.

By Distribution Channel

Retail pharmacies remain the dominant distribution channel given their accessibility and established role in prescription fulfillment. Online pharmacies are projected to register the fastest growth, propelled by telehealth expansion and direct-to-consumer digital health platforms.

Regional Outlook: Where Is the Semaglutide Market Growing Fastest?

North America led the market in 2025 with a 44.8% revenue share, driven by high U.S. diabetes and obesity prevalence — CDC data from January 2026 puts diagnosed diabetes at 12.0% of the U.S. population. Asia Pacific is expected to register the fastest CAGR of 15.3% through 2034 as rising metabolic-disease incidence, highlighted by Australia's diabetes prevalence climbing to 6.6% of adults, drives demand for long-acting treatment options. Within North America, the U.S. remains the largest single market; within Asia Pacific, China's large patient population and expanding domestic pharmaceutical capacity are the primary growth engine. Europe, led by Germany's well-structured healthcare system, rounds out the top three regions.

Competitive Landscape: Leading Semaglutide Companies

Key players profiled in the report include Novo Nordisk A/S, Sun Pharmaceutical Industries, Zydus Lifesciences, NATCO Pharma, Eris Lifesciences, Hangzhou Jiuyuan Gene Engineering, and Sandoz AG, who are focusing on generic development, strategic partnerships, and expanded delivery formats to strengthen market position across the Ozempic and type 2 diabetes segments outlined above. Recent moves include Novo Nordisk's June 2026 REIMAGINE Phase 3 data presentation and its ongoing Wegovy tablet commercialization push, both aimed at deepening global share.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching GLP-1 receptor agonist therapeutics, this report benchmarks semaglutide market share, segment-level pricing, and forecast data — by product, application, route of administration, distribution channel, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points ahead of patent-cliff generic entry, and strategy teams tracking oral formulation adoption as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Automatic Tube Cleaning Systems Market

Fungal Staining Reagent Market

Amniotic Products Market

Polyvinyl Alcohol Market

Broth Market

Broth Market

Direct Energy Conversion Device Market

Paracetamol IV Market

Photoacoustic Imaging Market